FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4243314648> ?p ?o ?g. }

• W4243314648 endingPage "469" @default.
• W4243314648 startingPage "469" @default.
• W4243314648 abstract "1 April 2008 Dear Editor, RE: RESPONSE TO SCHEINBERG et al Thank you for the opportunity of responding to the letter by Adam Scheinberg et al. commenting on our case report: Botulinum Neurotoxin A: An Unusual Systemic Effect. Scheinberg et al. have provided timely reassurance by their careful audit of adverse events, suggesting that the incidence of adverse events in percentage terms is low and all adverse events recorded were self-limiting. However, their average dose was lower than that used in the patient reported by Howell and in addition, it is my understanding that they do not administer botulinum toxin A (BTX-A) under general anaesthetic but utilise a combination of other techniques principally nitrous oxide. The patient referred to in our case report unfortunately represented with an insufficiency fracture of his femur and required a general anaesthetic on several occasions to internally fix his fracture, to replace a fixation rod and then to remove the fixation rod after a fracture healing. He was noted to have significant respiratory distress after each general anaesthetic even though our anaesthetic team were aware of his particular problems. It may be the combination of a relatively high dose of BTX-A and general anaesthesia which puts vulnerable patients at particular risk. However, unfortunately, our case report may have been the ‘canary in the mineshaft’. Since we submitted this case report, 16 deaths related to the administration of various forms of BTX-A have been reported to the Federal Drug Administration in the United States. We understand that four of these deaths may have been in children with cerebral palsy. In addition, a child in Switzerland has died after multilevel injection of BTX for spasticity related to cerebral palsy. In the light of this recent information and in consideration of our patient's adverse event published in the Journal of Paediatrics and Child Health, we have undertaken the following steps: We have suspended injections of BTX-A in children at Gross Motor Function Classification System (GMFCS) level V. We have set a revised upper dose limit of 18 units/kg of the Botox preparation from Allergan. Those of us who use this most useful drug are having to come to terms with the possibility of severe adverse events and even deaths, in children with cerebral palsy. The careful audit of adverse events by Scheinberg et al. is somewhat reassuring. We agree entirely that a prospective study of large cohorts of children would be very timely. Yours sincerely" @default.
• W4243314648 created "2022-05-12" @default.
• W4243314648 creator A5037576805 @default.
• W4243314648 creator A5047243893 @default.
• W4243314648 date "2008-07-01" @default.
• W4243314648 modified "2023-10-18" @default.
• W4243314648 title "Letters to the Editor" @default.
• W4243314648 doi "https://doi.org/10.1111/j.1440-1754.2008.01344.x" @default.
• W4243314648 hasPublicationYear "2008" @default.
• W4243314648 type Work @default.
• W4243314648 citedByCount "0" @default.
• W4243314648 crossrefType "journal-article" @default.
• W4243314648 hasAuthorship W4243314648A5037576805 @default.
• W4243314648 hasAuthorship W4243314648A5047243893 @default.
• W4243314648 hasBestOaLocation W42433146481 @default.
• W4243314648 hasConcept C126322002 @default.
• W4243314648 hasConcept C127413603 @default.
• W4243314648 hasConcept C141071460 @default.
• W4243314648 hasConcept C141983124 @default.
• W4243314648 hasConcept C162324750 @default.
• W4243314648 hasConcept C187736073 @default.
• W4243314648 hasConcept C188198153 @default.
• W4243314648 hasConcept C197934379 @default.
• W4243314648 hasConcept C199521495 @default.
• W4243314648 hasConcept C2776634555 @default.
• W4243314648 hasConcept C2776983577 @default.
• W4243314648 hasConcept C42219234 @default.
• W4243314648 hasConcept C71924100 @default.
• W4243314648 hasConcept C78519656 @default.
• W4243314648 hasConceptScore W4243314648C126322002 @default.
• W4243314648 hasConceptScore W4243314648C127413603 @default.
• W4243314648 hasConceptScore W4243314648C141071460 @default.
• W4243314648 hasConceptScore W4243314648C141983124 @default.
• W4243314648 hasConceptScore W4243314648C162324750 @default.
• W4243314648 hasConceptScore W4243314648C187736073 @default.
• W4243314648 hasConceptScore W4243314648C188198153 @default.
• W4243314648 hasConceptScore W4243314648C197934379 @default.
• W4243314648 hasConceptScore W4243314648C199521495 @default.
• W4243314648 hasConceptScore W4243314648C2776634555 @default.
• W4243314648 hasConceptScore W4243314648C2776983577 @default.
• W4243314648 hasConceptScore W4243314648C42219234 @default.
• W4243314648 hasConceptScore W4243314648C71924100 @default.
• W4243314648 hasConceptScore W4243314648C78519656 @default.
• W4243314648 hasIssue "7-8" @default.
• W4243314648 hasLocation W42433146481 @default.
• W4243314648 hasOpenAccess W4243314648 @default.
• W4243314648 hasPrimaryLocation W42433146481 @default.
• W4243314648 hasRelatedWork W1960168413 @default.
• W4243314648 hasRelatedWork W2029127390 @default.
• W4243314648 hasRelatedWork W2040095225 @default.
• W4243314648 hasRelatedWork W2058081633 @default.
• W4243314648 hasRelatedWork W2078023004 @default.
• W4243314648 hasRelatedWork W2098071496 @default.
• W4243314648 hasRelatedWork W2113305012 @default.
• W4243314648 hasRelatedWork W2409883922 @default.
• W4243314648 hasRelatedWork W3058363466 @default.
• W4243314648 hasRelatedWork W4246216675 @default.
• W4243314648 hasVolume "44" @default.
• W4243314648 isParatext "false" @default.
• W4243314648 isRetracted "false" @default.
• W4243314648 workType "article" @default.